Close Menu

NEW YORK – Immuno-oncology imaging firm ImaginAb has initiated a Phase II trial of its positron emission tomography (PET) imaging agent [89] Zr-Df-IAB22M2C at Dana-Farber Cancer Institute.

The imaging agent uses antibody fragments, so called "minibodies," engineered by ImaginAb to target CD8-positive T cells, and illuminate them with the help of PET imaging. The platform is being developed to provide a whole-body snapshot of immune activity, including that of cancer lesions, which in turn could be used to tailor treatment more precisely to patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.